PROTAGONIST THERAPEUTICS INC (PTGX) Institutional Buying Activity
Institutional investors tracked by InsiderSet increased exposure to PROTAGONIST THERAPEUTICS INC (PTGX) during the quarter ended June 30, 2026 through a combination of new purchases and expanded existing positions disclosed in SEC Form 13F filings.
Several hedge funds and long-term asset managers reported increases in PTGX exposure during the latest reporting period based on SEC Form 13F filings.
Institutional buying activity can provide insight into investor conviction, sector allocation trends, and smart money positioning toward PROTAGONIST THERAPEUTICS INC (PTGX). InsiderSet tracks quarterly accumulation trends, new institutional positions, ownership increases, and estimated performance of newly disclosed holdings using SEC filing data and recent market prices.
No data available.
Frequently asked questions about PTGX activity
Which institutional owners are buying PTGX?
Institutional owners buying PTGX include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in PTGX activity?
"Buy" means an investor increased their reported position in PTGX compared to the prior reporting period. This reflects growing exposure to PROTAGONIST THERAPEUTICS INC (PTGX) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in PTGX increasing?
Institutional interest in PTGX can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.